| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Diller Medical Inc is a Bluffton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IMAC Regeneration Centers offers long-term solutions for chronic musculoskeletal conditions without surgery or opioids. This state-of-the-art medical treatment utilizes a combination of regenerative medicine and rehabilitation to prevent the most common unnecessary surgeries, including spinal fusion and laminectomy, and knee and hip replacements. Each of these surgeries require an opioid prescription 99.9% of the time, leading to a high risk of addiction and never returning to work.
PREtest Consult is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aria Medical is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.